# A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

> **NCT02953678** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 71 (actual)

## Conditions studied

- Graft-versus-host Disease (GVHD)

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Prednisone or methylprednisolone

## Key facts

- **NCT ID:** NCT02953678
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-30
- **Primary completion:** 2018-01-31
- **Final completion:** 2019-08-14
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953678, "A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02953678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*